Peptides · Longevity & Cellular Health

NAD+

Nicotinamide adenine dinucleotide · NMN · NR (precursors)

Supplements & IV clinics · claims outpace evidence

Not a peptide — a coenzyme central to cellular energy metabolism.

Not a peptide at all, but impossible to leave out of the longevity conversation: NAD+ is a coenzyme every cell uses to produce energy, and its decline with age has spawned an industry of IV drips and precursor supplements (NMN, NR).

At a glance

  • Coenzyme required for cellular energy production; declines with age
  • Precursors (NMN, NR) reliably raise blood NAD+ in trials
  • Hard clinical outcomes in humans remain unproven
  • TGA permitted oral NMN in Dec 2025; FDA reversed its NMN ban in 2025

How it works

NAD+ powers the metabolic reactions that convert food to energy and fuels sirtuins and PARPs — enzymes involved in DNA repair and cellular stress responses. Levels fall with age, which is the rationale for supplementing precursors like NMN and NR that the body converts to NAD+.

What the research shows

Precursor supplements reliably raise blood NAD+ levels in human trials. What hasn't been shown is that this translates into meaningful health or longevity outcomes — human trials to date show modest or mixed effects on metabolic markers, and IV NAD+ has little published evidence at all.

Regulatory status

Australia

NAD+ IV infusions are offered by clinics under medical supervision. For supplements the picture changed in December 2025, when the TGA permitted oral NMN as a listed-medicine ingredient — capped at 500 mg/day for up to 12 weeks, and initially exclusive to the sponsoring company until late 2027. NAD+ itself and NADH remain non-permitted ingredients; nicotinamide riboside (NR) is permitted.

Worldwide

In the US the FDA reversed course in September 2025, allowing NMN back into dietary supplements after excluding it in 2022. NR remains available as a supplement in most markets.

Latest NAD+ articles

26 September 2026

NAD+ Research: NR vs NMN, 65 People vs 6

Two 2026 NAD+ trials, two headlines: a 65-person NR vs NMN comparison and a 6-person PK study. What the evidence shows and the TGA rules in Australia.

This is general information, not medical advice. retatrutide.net.au is an independent publication. Unless stated otherwise above, this compound is not an approved medicine in Australia, and this page does not endorse or facilitate its use. Speak to a registered health practitioner about any treatment decision.

Stay informed

Be first to know.
When it reaches Australia.

Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:

  • The latest clinical trial results and news from Eli Lilly
  • Updates on TGA regulatory progress in Australia
  • How and where to access Retatrutide when it becomes available
  • Occasional information from retatrutide.net.au and our affiliated partners
TGA review expected 2027 — subscribers hear the moment the status changes.

Get the free guide + updates

Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.

Sign up now
NAD+ — Research, Evidence & Australian Status | Retatrutide Australia